Cadherin-13 (CDH13)

Cadherin-13 (CDH13) is a GPI-anchored atypical cadherin and a member of the cadherin superfamily, primarily expressed on the cell surface without a transmembrane or intracellular domain[1][2][3][4]. Unlike classical cadherins, it mediates weak homophilic and possibly heterophilic cell-cell interactions and acts more as a regulatory protein, rather than an adhesive one[1][3][5]. CDH13 regulates neural network excitability by localizing to GABAergic (inhibitory) presynapses, especially those of parvalbumin- and somatostatin-expressing interneurons[2][3][7]. It negatively regulates inhibitory synaptic transmission and is important for maintaining the excitation/inhibition balance in the nervous system[2][3]. CDH13 is involved in the control of axon guidance and maturation during neurodevelopment and offers vascular endothelial cells protection from apoptosis under oxidative stress[1]. Genetic and epigenetic alterations of CDH13 are linked to several neurodevelopmental (e.g. ADHD, autism, depression), psychiatric, cardiovascular, and oncologic diseases[2][3][5][7]. There are currently no established direct CDH13-targeting drugs, but its biology makes it a relevant therapeutic and diagnostic target, especially as a disease biomarker.

Other names

Cadherin-13CDH13CDHHH-cadherinT-cadherinT-cadheart cadherinP105truncated cadherinH-cadherin (heart)cadherin 13

Drugs targeting cadherin-13 would likely modulate cell signaling by altering cell adhesion, E/I balance, or synaptic transmission; however, specific approved drugs or clinical ligands for CDH13 are not delineated in the current literature[1][2][3][7].